Lenvatinib for the treatment of hepatocellular carcinoma-a real-world multicenter Australian cohort study.

ABSTRACT:

Introduction

Hepatocellular carcinoma (HCC) is a serious complication of chronic liver disease. Lenvatinib is an oral multikinase inhibitor registered to treat advanced HCC. This study evaluates the real-world experience with lenvatinib in Australia.

Methods

We conducted a retrospective cohort study of patients treated with lenvatinib for advanced HCC between July 2018 and November 2020 at 11 Australian tertiary care hospitals. Baseline demographic data, tumor characteristics, lenvatinib dosing, adverse events (AEs) and clinical outcomes were collected. Overall survival (OS) was the primary outcome. Progression free survival (PFS) and AEs were secondary outcomes.

Results

A total of 155 patients were included and were predominantly male (90.7%) with a median age of 65 

SUBMITTER: Patwala K 

PROVIDER: S-EPMC9525325 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature